Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 103 clinical trials
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

progressed to acute myeloid leukemia. Ruxolitinib, a JAK1/2 inhibitor, and enasidenib an IDH2 inhibitor are effective and tolerable treatments for patients with myelofibrosis (MF) and acute myeloid leukemia

Accepts healthy volunteers
  • 0 views
  • 29 May, 2022
  • 3 locations
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

This randomized phase I/II trial studies the best dose and side effects of durvalumab and to see how well it works with or without lenalidomide in treating patients with cutaneous or peripheral T cell lymphoma that has come back and does not respond to treatment. Monoclonal antibodies, such as durvalumab, …

monoclonal protein
systemic therapy
lymphoma
cutaneous lymphoma
anaplastic large cell lymphoma
  • 64 views
  • 25 Mar, 2022
  • 1 location
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.

  • 0 views
  • 01 Apr, 2021
  • 6 locations
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

This phase I trial finds the appropriate parsaclisib dose level in combination with romidepsin for the treatment of T-cell lymphomas that have come back (relapsed) or that have not responded to standard treatment (refractory). The other goals of this trial are to find the proportion of patients whose cancer is …

systemic steroids
avid
anaplastic large cell lymphoma
brentuximab
prednisone
  • 1 views
  • 01 May, 2022
  • 1 location
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma (IMAGINE)

This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid …

cyclophosphamide
large cell lymphoma
flow cytometry
anaplastic large cell lymphoma
experimental drug
  • 2 views
  • 22 Oct, 2022
  • 5 locations
Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients (TOTEM)

recommended Phase II dose (RP2D). Dose escalation will be conducted according to a 'Rolling-6' based study design with 3 dose levels for repotrectinib: 80 mg once a day (QD), 160 mg QD or 160 mf QD during 14

lung carcinoma
osimertinib
erlotinib
ROS1
neutrophil count
  • 0 views
  • 04 Oct, 2022
  • 4 locations
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. …

adenocarcinoma
hodgkin's disease
breast cancer
nivolumab
pembrolizumab
  • 14 views
  • 22 Mar, 2022
  • 1 location
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

This phase I/II trial studies the side effects and best dose of modified umbilical cord blood immune cells (natural killer [NK] cells) combined with the antibody AFM13 (AFM13-NK) and AFM13 alone in treating patients with CD30 positive Hodgkin lymphoma or non-Hodgkin lymphoma that has come back (recurrent) or does not …

lymphoma
classical hodgkin lymphoma
ejection fraction
brentuximab vedotin
b-cell lymphoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

This study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment. This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab …

avid
hodgkin's disease
lymphoma
adult t-cell leukemia/lymphoma
measurable disease
  • 25 views
  • 04 Oct, 2022
  • 2 locations
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth …

growth factor
monoclonal protein
anaplastic large cell lymphoma
panniculitis
pembrolizumab
  • 5 views
  • 04 Oct, 2022
  • 3 locations